Tag Archives: FDML

Hot Blue Chip Stocks To Watch For 2018

March 20, 2017: Markets opened slightly lower Monday and traded close to the break-even line all day. Leading indicators and consumer sentiment readings were both strong. Only the materials sector traded high late in the afternoon while energy and utilities were the laggards. The blue chips were performing best. WTI crude oil for April delivery settled at $48.22 a barrel, down 1.2% on the day. April gold added 0.3% on the day to settle at $1,234.00. Equities were headed for a mixed close shortly before the bell as the DJIA traded up 0.03% for the day, the S&P 500 traded down 0.14%, and the Nasdaq Composite traded up 0.02%.

Stocks traded very near the break-even line just minutes before the closing bell. The closing tally could finish with either a small gain or a small loss for any or all of the indexes.

The DJIA stock posting the largest daily percentage gain ahead of the close Monday was Caterpillar Inc. (NYSE: CAT) which traded up 2.66% at $95.38. The stock’s 52-week range is $69.04 to $99.46. Volume was roughly 15% below the daily average of around 5 million shares. The company reported a 1% decline in February retail sales this morning, the best year-over-year mark in more than 4 years.

Hot Blue Chip Stocks To Watch For 2018: Sears Holdings Corporation(SHLD)

Advisors’ Opinion:

  • [By Cooper Creagan]

    On Sept. 1, Keith saw a red X on his charts, indicating that Sears Holding Corp. (NYSE: SHLD) was headed for yet another round of misery. Later that month, he recommended a put option on the struggling retailer.

  • [By Motley Fool Staff]

    In this segment ofIndustry Focus: Consumer Goods, analyst Vincent Shen and contributor Adam Levine-Weinberg turn their attention to several recent initiatives that could help stabilize sales at department stores. They also dig into J.C. Penney’s strategy for profiting from the potential demise of Sears Holdings (NASDAQ:SHLD).

  • [By Adam Levine-Weinberg]

    These trends have already forced nearly a dozen retailers to file for bankruptcy this year — and it’s only April. Among the most troubled retailers, Sears Holdings (NASDAQ:SHLD) stands out as by far the largest. If Sears were to go bankrupt, it could have far-reaching consequences. However, while Sears is probably doomed, it is likely to limp on for a couple more years.

  • [By Joe Tenebruso]

    Sears Holdings (NASDAQ:SHLD) — the parent company of Sears and Kmart — may not survive the year, with these once iconic retailers besieged by a poisonous combination of plunging sales, massive losses, and dwindling cash reserves. CEO Eddie Lampert has turned to creative financing deals and fire sales of most of Sears’ best assets to raise the capital needed to fund the company’s operations, but even these drastic measures are likely to only delay Sears’ seemingly inevitable demise.

  • [By Daniel B. Kline]

    The CEO wanted to make it clear that while it’s closing stores, J.C. Penney remains committed to having brick-and-mortar locations. He also seemed to want to distance the company from rival Sears Holdings (NASDAQ:SHLD), which has been cutting stores quickly, with seemingly no end in sight.

  • [By Rich Duprey]

    Despite the heady picture, Whirlpool’s stock trades at just 10 times next year’s earnings estimates, which analyst consensus forecasts place at around $17.60 per share, a 12% rise year over year. Perhaps weighing on the outlook is the potential for Sears Holdings (NASDAQ:SHLD) to go bankrupt, which would be a loss of a major distribution channel for the owner of Whirlpool, Maytag, and Amana appliances.

Hot Blue Chip Stocks To Watch For 2018: Sharp Corp (SHCAF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The company is partnering with Chinese company OXi Technology (in which it also made a strategic investment) for developing fingerprint sensor under glass and in the bezel of smartphones. Its fingerprint sensor business received a boost from the Samsung (OTC:SSNLF) S8 and S8+ design wins (as well as Sharp’s (OTCPK:SHCAF) Aquos R and ZTE ZMax Pro).

Hot Blue Chip Stocks To Watch For 2018: Federal-Mogul Holdings Corporation(FDML)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.

Hot Blue Chip Stocks To Watch For 2018: Bank of Nova Scotia (The)(BNS)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Bank of Nova Scotia (The) (NYSE: BNS): Free Stock Analysis Report
     
    Banco Bilbao Viscaya Argentaria S.A. (NYSE: BBVA): Free Stock Analysis Report
     
    Credicorp Ltd. (NYSE: BAP): Free Stock Analysis Report
     
    Bank of N.T. Butterfield & Son Limited (The) (NTB): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.

Hot Blue Chip Stocks To Watch For 2018: CDI Corporation(CDI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CDI Corp. (NYSE: CDI) got a boost, shooting up 32 percent to $8.20 as the company agreed to be acquired by AE Industrial Partners for $8.25 per share in cash.

Hot Medical Stocks To Own For 2018

Cell Medx Corp (OTCBB: CMXC) is in the news for insider trading. Reading a headline with insider trading generally sends chills, especially if you are the part of the management team of said company. But lets consider for a moment that this could be a buy opportunity, or at least an event worthy of shining the spotlight on a small(ish) bio-tech firm.

Cell Medx Corp (OTCBB: CMXC) is an early stage bio-tech firm focusing on the discovery, development and commercialization of therapeutic products. With treatments for diabetes, Parkinsons Disease and high blood pressure in their wheelhouse, Cell Medx is plugged into three of the most significant medical conditions that affect the population.

The company recently announced it had completed the registration process with the FDA, and that it is conducting ongoing clinical trials for a diabetes therapy. According to their most recent financials, they eliminated over $800k of liabilities from their balance sheet, and they have a strong cash reserve, indicators that they are well positioned for reverse mergers or acquisition by a larger, more established company.

Hot Medical Stocks To Own For 2018: Nuveen Select Tax Free Income Portfolio(NXP)

Advisors’ Opinion:

  • [By Eric Volkman]

    Income investors might be wary of Qualcomm, as the company loves to spend its money — at times, its dividend payouts and share buybacks have exceeded free cash flow. Compounding that matter, the company should soon close the door on its acquisition of European peer NXP Semiconductor (NYSE:NXP), a deal with an estimated enterprise value of $47 billion.

Hot Medical Stocks To Own For 2018: Radient Technologies (RTI)

Advisors’ Opinion:

  • [By Matthew Briar]

    There’s an old business adage…. it’s not so much what you know, but who you know. If that’ s truly the case (and it is), then shareholders in Radient Technologies Inc (CVE:RTI) should be elated. The newest member of the Board of Directors that not already knows a lot of the right people, but has pretty much done all of things Radient would like to accomplish in the near future. That is, he was on the board for another ingredient and chemical company that was eventually acquired, but he also holds a masters degree in engineering. He can do it all, understanding the art and science of the business.

    It’s yet another reason for RTI investors to be enthused.

    Radient Technologies isn’t exactly a new company, but it’s relative notoriety is a fairly new phenomenon.

    The organization, in simplest terms, has developed an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which drives out the targeting ingredient or component much faster than more conventional extraction methods. In fact, the pressure-driven process outperforms the conventional extraction on pretty much every front. That is, the technique reduces the extraction time from hours to minutes, delivers a higher active ingredient purity, increases the recovery of actives from often scarce biomass, and uses much less solvent and energy than the more typical approach.

    The technique can, and already has, created natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics.

    The company’

  • [By Matthew Briar]

    Although the past several years have been very good ones for the cannabis — marijuana and hemp — industry, it’s still mostly being done in an old, artisan-style fashion. Most companies haven’t figured out a way of scaling up their outputs by improving their operating/production efficiency, even though the market’s growth has merited. Radient Technologies Inc (CVE:RTI) represents that next evolution of the cannabinoid business, introducing a new approach to extracting cannabinoids from cannabis plants that will not only improve yields, but create a superior, purer product.

    Canada-based Radient Technologies has developed — and patented – an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along. To fully appreciate why it matters, however, one has look at the approach other ingredients suppliers are utilizing now.

    With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated to 50 degrees Celsius (or more), and over the course of several hours, the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.

    It works, but it’s hardly ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, a lot of things you don’t want to extract can still be found in the extract, lowering the quality and purity of the ingredient.

    Radient Technologies’ microwave assisted processing changes all of this.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which

  • [By Jim Robertson]

    Small cap Radient Technologies (CVE: RTI) is focused on extracting, isolating and purifying food/nutraceutical ingredients (colourings, flavourings, preservatives etc) and pharmaceutical raw materials from its20,000 square foot manufacturing plant in Edmonton, Alberta. The Companyworks with global brands across a range of industries (including Food and Beverage, Nutrition and Supplements, Pharmaceuticals, Personal Care and Cosmetics and Biofuel) andengageswithits clients in three distinct phases:

  • [By Matthew Briar]

    At first glance, a new set of rules from the Drug Enforcement Agency unveiled in the middle of December looked like it posed a problem for cannabis-newcomer Radient Technologies Inc (CVE:RTI). By assigning a controlled substances code number to ‘marijuana extract,’ simultaneously distinguishing (and acknowledging the differences of marijuana, hemp and their derivatives as Schedule I substances. As the ruling’s language explained, “This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions.”

    It presents something of an uncertainty, as it was not clear of the DEA also meant hemp and cannabis extracts when it used the term ‘marijuana extract.’ After all, the Drug Enforcement Agency has thus far done a poor job of distinguishing between hemp and marijuana, but has generally erred on the side of grouping everything as marijuana…. even if it didn’t cause a ‘high,’ and even if it did provide a medical benefit. If that was indeed the case, Radient Technologies may well be a non-starter in its quest to get into the cannabis business.

    No need to worry. Though it took weeks to get some much-needed clarification, the DEA has finally explained what it was saying two months ago. Indeed, the new ruling may actually help the medical marijuana — cannabis — along. DEA spokesman Russ Baer said in an e-mail to The Cannabist, “(The rule change) recognizes that there is a potential medical benefit to some of the cannabinoids.”

    Some still worry the wording of the law essentially, even if unintentionally, puts cannabinoids (or CBD) under the purveyance of the DEA; it’s currently not. Even so, if nothing else the ruling has the government moving towards clarity, after acknowledging CBD — the healthy version of the cannabis, and not the one that gets you high — has medical value. The next step is clarifying ho

  • [By James E. Brumley]

    Some of the stories about how cannabis has changed lives for the better are nothing less than astounding. Take Illinois resident Darren Miller as an example. In 2015 Miller was diagnosed with lung cancer that was later deemed terminal. Miller underwent chemotherapy, without much hope, but also began using high-THC Indica cannabis oil. Miller is alive today, and arguably shouldn’t be.

    Then there’s Floridian Branden Petro. Not only does Petro suffer epilepsy, he commonly experiences seizures stemming from the condition. Nothing has stopped the seizures as quickly or effectively as 200 milligram worth of THC cannabis oil, administered as a nasal spray. Within 20 seconds of using it, it’s as of the seizure never happened.

    And there are millions of other such (and less dramatic) examples, all pointing in the same direction – cannabis has medical value on multiple fronts. Not facilitating its commercialization is a wasted opportunity.

    It’s a notion that’s far from lost on the people that have built Canadian-based Radient Technologies Inc (CVE:RTI) from the round up, recently inking a deal with supplier of cannabinoid extracts, Aurora Cannabis.

    It’s a real accolade. Aurora is one of the largest licensed producers of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), and recently began construction on an unprecedented 800,000 square foot production facility in Leduc County, Alberta. This facility, known as “Aurora Sky”, is anticipated to be capable of producing in excess of 100,000 kg of high-quality, low-cost marijuana per year.

    In most regards though, Radient Technologies is the big winner of the deal, as the partnership is apt to put its high-tech facility in full demand, helping to advance the advent of cannabis in all its potential glory.

    It’s a rather amazing science, really. Radient Technologies uses an ingredient-extraction process called microwave assisted proc

Hot Medical Stocks To Own For 2018: Federal-Mogul Holdings Corporation(FDML)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.

Hot Medical Stocks To Own For 2018: BioLineRx Ltd.(BLRX)

Advisors’ Opinion:

  • [By William Romov]

    Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biopharmaceutical stockBioline RX Ltd (NASDAQ: BLRX) as a speculative buy:

Hot Medical Stocks To Own For 2018: Brown & Brown, Inc.(BRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    BMO also upgraded Arch Capital Group (ACGL), Brown & Brown (BRO), and Travelers (TRV).

    Shares of American International Group have declined 0.4% to $65.60 at 3:36 p.m. today, whileArch Capital Group has gained 2% to $87.90,Brown & Brown has advanced 0.5% to $44.65, andTravelers has risen 1.3% to $120.79.

Hot Medical Stocks To Own For 2018: 3D Systems Corporation(DDD)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows ExOne Co along with other small cap 3D printing stocks like3D Systems Corporation (NYSE: DDD), Stratasys, Ltd (NASDAQ: SSYS) and Voxeljet AG (NYSE: VJET) all peaking in 2013/2014 with the bubble clearly bursting since then:

  • [By Jack Delaney]

    Here are 10 virtual reality stocks to watch in 2017, with today’s opening price (Feb. 22) and the year-to-date (YTD) return thus far:

    3D Systems Corp. (NYSE: DDD); $17.12; +26.71% YTDUniversal Display Corp. (Nasdaq: OLED); $71.60; +25.49% YTDAdvanced Micro Devices Inc. (Nasdaq: AMD); $14.30; +24.22% YTDFacebook Inc. (Nasdaq: FB); $133.60; +18.64% YTDAdobe Systems Inc. (Nasdaq: ADBE); $119.67; +15.93% YTDSony Corp. (NYSE ADR: SNE); $31.29; +11.49% YTDAlphabet Inc. (Nasdaq: GOOGL); $848; +7.49% YTDAmbarella Inc. (Nasdaq: AMBA); $57.85; +6.26% YTDMicrosoft Corp. (Nasdaq: MSFT); $64.33; +3.16% YTDRockwell Collins Inc. (NYSE: COL); $93.97; +0.97% YTD

    The virtual reality industry could reach $33.9 billion in value by 2022, which is why virtual reality stocks are more popular than ever.

  • [By Beth McKenna]

    While Stratasys’ stock is still down significantly from its all-time high, it’s showing signs of life this year. It’s gained 17% in 2017, through March 3, outpacing rival 3D Systems’ (NYSE:DDD)9.3% gain and the S&P 500’s total return of 6.9%. Shares of 3D Systems had been riding higher in 2017, through plummeted 10% after the company announced earnings on Feb. 28. Quarterly revenue and 2017 revenue guidance came in lighter than Wall Street analysts were expecting.

value investing

Today, it was all about oil afterOPEC “reached an understanding” on capping oil production. And that made Murphy Oil (MUR) the hottest stock in the S&P 500.

Getty Images

Murphy Oil soared 11% to$28.91 today, easily topping the S&P 500′s 0.5% rise to2,171.37.Front month Nymex Crude futures climbed $2.38 per barrel, or 5.3% to $47.05, while the Energy Select Sector SPDR ETF (XLE) jumped 4.3% to$69.78.

Murphy Oil, meanwhile, is one of those oil companies that’s particularly sensitive to changesin the price of oil. Oil goes up, Murphy gains. Oil goes down, Murphy drops. Simple. And boy did oil go up, thanks to OPEC.

Thanks to today’s 11% move, the stock now has a market capitalization of $4.5 billion. Not bad for a company that lost $2.3 billion on sales of $2.7 billion in 2015.

value investing: Aquinox Pharmaceuticals, Inc.(AQXP)

Advisors’ Opinion:

  • [By Lee Jackson]

    The Baker Brothers biotech hedge fund bought a block of 398,062 shares of Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) last week. At a per-shareprice of $17.18, the total for the trade came to$6,836,813.

value investing: Barclays PLC(BCS)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Barclays PLC (NYSE: BCS) was raised to Overweight from Equal Weight at Morgan Stanley. Its American depositary sharesclosed up 2.6% at $11.36 on Thursday and were indicated up 1.2% at $11.50 on Friday. The52-week range is $6.76 to $12.05.

  • [By WWW.THESTREET.COM]

    Banco Santander (SAN) : “I prefer Barclays (BCS) , but let’s wait and see what the other banks have to say”

    ProLogis (PLD) : “I am not a fan of that group right now, but that one is best of breed.”

value investing: Chuy's Holdings, Inc.(CHUY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Del Taco Restaurants now outperforming Mexican restaurant stock peers such as mid cap Chipotle Mexican Grill, Inc (NYSE: CMG) and small caps El Pollo LoCo Holdings Inc (NASDAQ: LOCO), Fiesta Restaurant Group Inc (NASDAQ: FRGI) and Chuy’s Holdings Inc (NASDAQ: CHUY) have mostly been drifting lower lately:

  • [By Peter Graham]

    A long term performance chart shows El Pollo LoCo Holdings having fallen below its IPO price for retail investors, butsharesappear to have stabilized over the past year and a halfwhile potentialpeers like small capFiesta Restaurant Group Inc (NASDAQ: FRGI) and large cap Chipotle Mexican Grill, Inc (NYSE: CMG) have performed better in the past and small cap Chuy’s Holdings Inc (NASDAQ: CHUY) is moving sideways:

  • [By Peter Graham]

    A long term performance chart shows Chipotle Mexican Grills shares back to breakeven while of the small caps peers, El Pollo LoCo Holdings Inc (NASDAQ: LOCO) has had the worst performance, Fiesta Restaurant Group Inc (NASDAQ: FRGI) is off its 2015s peak and Chuy’s Holdings Inc (NASDAQ: CHUY) has been a mixed performer:

value investing: Federal-Mogul Holdings Corporation(FDML)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.

value investing: Coherus BioSciences, Inc.(CHRS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Coherus Biosciences Inc (NASDAQ: CHRS) shares shot up 23 percent to $13.70 after the company announced plans to raise up to $150 million in a private placement.

  • [By Lisa Levin] Gainers
    Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter.
    Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba.
    Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision.
    Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results.
    Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday
    Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter.
    AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday.
    Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share.
    Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday.
    Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday.
    Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Ben Levisohn]

    Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:

    Agence France-Presse/Getty Images

    The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…

    Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.

    Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.

Top High Tech Stocks To Own Right Now

U.S. equities notched another new record high on Thursday, pushing the Dow Jones Industrial Average ever closer to the 20,000 threshold as the post-election melt up continues.

The catalyst was another rout in the bond market which continues to pull money out of fixed-income into the stock market as investors chase returns. The impetus was a surprise announcement overnight that the European Central Bank would extended its bond-buying program more than expected (through year-end 2017) while also trimming the pace of monthly purchases from 80 billion euro to 60 billion.

This was a “dovish taper,” which, when combined with the expected Federal Reserve rate hike next week and the inflationary expectations surrounding President-elect Trump’s fiscal stimulus plans, further lifted long-term interest rates and thus, lower bond prices.

The 10 Best Index Funds for 2017, 2018, 2019 …

In the end, the Dow Jones Industrial Average added 0.3%, the S&P 500 gained 0.2%, the Nasdaq Composite wafted up 0.4% and the Russell 2000 ended 1.6% higher.

Top High Tech Stocks To Own Right Now: Nabors Industries Ltd.(NBR)

Advisors’ Opinion:

  • [By Wayne Duggan]

    While Loop maintains a Buy rating on all of the stocks mentioned above, Guggenheim analyst Michael LaMotte isn’t quite so bullish on the sector. Earlier this week, LaMotte downgraded the following oil services stocks from Buy to Neutral:

    Baker Hughes Incorporated (NYSE: BHI)
    Fairmount Santrol Holdings Inc (NYSE: FMSA)
    Helmerich & Payne, Inc. (NYSE: HP)
    Nabors Industries Ltd. (NYSE: NBR)
    Schlumberger Limited. (NYSE: SLB)
    Halliburton
    Superior Energy Services

    Guggenheim also cut its 2017 oil price forecast from $55 to $48/bbl.

  • [By Craig Jones]

    Pete Najarian was watching Nabors Industries Ltd. (NYSE: NBR). He said that the stock has been trading in a range between $8 and $18 over the last 52 weeks and although it spiked 2.82 percent on Wednesday, it's still close to the lower end of the range. Anticipating a move higher, traders were buying the June 11 calls for $0.30. Around 6,000 contracts were bought in the first half of the session. The trade breaks even at $11.30 or 10.78 percent above the current market price. Pete Najarian decided to buy the calls and he is going to hold them for 4-5 weeks.

  • [By Ben Levisohn]

    Last night, Weatherford International (WFT) reported a smaller than expected loss and announcing an alliance with Nabors Industries (NBR)–and the news was celebrated by the market.

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Jon Najarian spoke about Nabors Industries Ltd. (NYSE: NBR). He said that somebody bought 6,500 contracts of the July 11 calls for $0.50 in the first half of the session. The trade breaks even at $11.50 or 16.28 percent above the current market price. Jon Najarian has a long position in the name and he is planning to hold it for a month.

  • [By Jon C. Ogg]

    Nabors Industries Ltd. (NYSE: NBR) rose by 22.3% to $16.11 on Wednesday. Its volume of 17.4 million shares was about 2.5 times normal trading volume. Nabors has a consensus analyst price target of $15.04 and a 52-week trading range of $4.93 to $16.50. The company has a total market cap of $4.6 billion.

Top High Tech Stocks To Own Right Now: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top High Tech Stocks To Own Right Now: Federal-Mogul Holdings Corporation(FDML)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.